Design, synthesis, and docking of novel thiazolidine‐2,4‐dione multitarget scaffold as new approach for cancer treatment

Abstract

Abstract Novel thiazolidine‐2,4‐diones have been developed and estimated as conjoint inhibitors of EGFR T790M and VEGFR‐2 against HCT‐116, MCF‐7, A549, and HepG2 cells. Compounds 6a, 6b , and 6c were known to be the dominant advantageous congeners against HCT116 (IC 50 = 15.22, 8.65, and 8.80 µM), A549 (IC 50 = 7.10, 6.55, and 8.11 µM), MCF‐7 (IC 50 = 14.56, 6.65, and 7.09 µM) and HepG2 (IC 50 = 11.90, 5.35, and 5.60 µM) mass cell lines, correspondingly. Although compounds 6a, 6b , and 6c disclosed poorer effects than sorafenib (IC 50 = 4.00, 4.04, 5.58, and 5.05 µM) against the tested cell sets, congeners 6b and 6c demonstrated higher actions than erlotinib (IC 50 = 7.73, 5.49, 8.20, and 13.91 µM) against HCT116, MCF‐7 and HepG2 cells, yet lesser performance on A549 cells. The hugely effective derivatives 4e–i and 6a–c were inspected versus VERO normal cell strains. Compounds 6b, 6c, 6a , and 4i were found to be the most effective derivatives, which suppressed VEGFR‐2 by IC 50 = 0.85, 0.90, 1.50, and 1.80 µM, respectively. Moreover, compounds 6b, 6a, 6c , and 6i could interfere with the EGFR T790M performing strongest effects with IC 50 = 0.30, 0.35, 0.50, and 1.00 µM, respectively. What is more, 6a, 6b , and 6c represented satisfactory in silico computed ADMET profile.